Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage

Documenti analoghi

• Cost‐effectiveness analysis of human papillomavirus ( HPV ) genotyping strategies for management of HPV ‐positive women in cervical cancer screening
  di: Kelsi R. Kroon, et al.
  Pubblicazione: (2026)
• Controlled trial of cervical cancer screening frequency among human‐papillomavirus‐vaccinated women
  di: Mònica Ortega Llobet, et al.
  Pubblicazione: (2025)
• Elimination of cervical cancer by refined vaccination and screening
  di: Matti Lehtinen, et al.
  Pubblicazione: (2024)
• Clinically validated HPV assays offer comparable long‐term safety in primary cervical cancer screening: A 9‐year follow‐up of a population‐based screening cohort
  di: Anja Oštrbenk Valenčak, et al.
  Pubblicazione: (2024)
• Is the beneficial effect of multi‐cohort HPV vaccination on cervical cancer and precancerous lesions seen across all educational levels?
  di: Rose M. W. Rasmussen, et al.
  Pubblicazione: (2026)